I reported previously (Feb 2015) on the recovery from muscle injury of hip-replacement patients treated with PLX-PAD stem cells from Israel’s Pluristem. Follow-up data has now confirmed the results and expanded Phase III trials are being supported by the European … Continue reading →

I reported previously (see here) on the stem cell treatment of Israel’s Pluristem for radiation sickness. Pluristem’s four-year studies show that its placenta-based PLX-R18 cells are effective as a treatment for radiation damage to the gastrointestinal tract and bone marrow. … Continue reading →

I’ve reported previously (18 times) on Israeli biotech Pluristem’s PLX stem cell treatment for many life-threatening conditions. Recent lab trials with modified PLX cells showed significant inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin … Continue reading →

Israeli biotech Pluristem has been awarded two new patents in Hong Kong for two products – mesenchymal stem cells for the treatment of skeletal muscle damage or injury, and adherent cells to treat Critical Limb Ischemia and connective tissue regeneration. … Continue reading →

I previously reported (here) on the therapy from Israel’s Pluristem for treating patients exposed to lethal radiation doses. Pluristem is to join the US National Institute of Allergy and Infectious Diseases program designed to protect people from catastrophic incidents. http://www.jpost.com/Israel-News/US-government-to-stocking-Israeli-bio-tech-cure-to-lethal-radiation-in-2017-445620

Japan’s Fukushima Medical University and Israel’s Pluristem Therapeutics are to develop Pluristem’s PLX-R18 cells to treat acute radiation syndrome (ARS). Radiation continues to spread following the Fukushima nuclear plant disaster. http://www.timesofisrael.com/japan-turns-to-israeli-tech-to-treat-radiation-disease/

Stem cells from Israel’s Pluristem have been used in clinical tests to successfully treat bone marrow failure following total body exposure to high doses of radiation. http://www.timesofisrael.com/israeli-radiation-disease-treatment-passes-major-hurdle/ http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066549

Israel’s Pluristem Therapeutics has announced that the improvement in muscle force of hip-replacement patients treated with its PLX-PAD cells was 40-times better than those who received a placebo. http://www.globes.co.il/en/article-further-posiitive-trial-findings-for-pluristem-1001006064

Israel’s Pluristem announced that patients treated with PLX-PAD stem cells had a greater improved change of maximal voluntary muscle contraction force than the placebo group. The Phase I/II clinical trial shows that PLX cells can help repair orthopedic injuries including … Continue reading →

Placental eXpanded (PLX) cell treatment from Israel’s Pluristem has saved the life of a 45-year-old man who suffered from bone marrow failure after undergoing chemotherapy and a bone-marrow transplant, due to leukemia. There were no side effects and the man … Continue reading →